Oxford BioMedica PLC (OXBDF)

[marcusl2]

The most high profile was the world's first gene therapy for cancer, Kymriah, developed by Swiss firm Novartis with British biotech Oxford BioMedica.

Novartis' Kymriah, approved in the US, is the first so-called CAR-T cell therapy for cancer, a one-time treatment that works by modifying a patient’s cells so they can spot and kill cancer cells.
HTTP://www.telegraph.co.uk/business/2017/12/12/gsk-hails-progress-advanced-cancer-drug/

HTTPS://seekingalpha.com/article/4131387-novartis-nvs-highlights-ash-sabcs-slideshow?auth_param=1d8lsm:1d309p1:93c5affae499caa3b388802d8be6d971&uprof=82&dr=1



DLBCL in FIRST RELAPSE

Pages 4 and 5 make good reading

the cocktail of chemotherapies they receive come with considerable side effects, with many survivors experiencing serious health conditions later in life as a result of the treatment.
For parents of children with leukemia who have failed conventional treatments already, the decision to try CAR T-cells is easy. For the first parents that consent to the inevitable chemotherapy-free CAR T-cell only trial, it will be a leap of faith. If all goes well, their children will be the first ever to survive leukemia without any chemotherapy treatment.

In May this year Emily, the first patient to get CAR T-cells celebrated the milestone of being five years cancer-free. Undoubtedly there are still numerous challenges to overcome before CAR T-cells become a mainstream therapy for multiple cancer types, but in five years from now, hundreds if not thousands of others will be joining Emily in this currently unique club.
HTTPS://www.forbes.com/sites/victoriaforster/2017/12/12/chemotherapy-free-cancer-treatments-move-closer-to-reality/#66245bcd6676